By Adria Calatayud

AstraZeneca PLC said Monday that its Forxiga drug has been recommended in the European Union for patients with chronic kidney disease.

The drug--known as Farxiga in the U.S.--was recently approved there and is currently under review in Japan and other countries around the world, the pharmaceutical company said.

AstraZeneca said the EU approval was based on results from a Phase 3 trial which showed that the drug, on top of standard-of-care treatment, reduced the risk of the composite of a worsening in renal function, end-stage kidney disease and cardiovascular or renal death compared with the placebo.

Write to Adria Calatayud at adria.calatayud@dowjones.com

(END) Dow Jones Newswires

June 28, 2021 02:45 ET (06:45 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Astrazeneca Charts.